Matches in Nanopublications for { ?s ?p "[RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 12 of
12
with 100 items per page.
- NP285404.RAWK4LO-YgXUqMVjseQ5tlMDSvyGus6ilyXGCkJZ0g7mA130_assertion description "[RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP285404.RAWK4LO-YgXUqMVjseQ5tlMDSvyGus6ilyXGCkJZ0g7mA130_provenance.
- NP936426.RAbZ3G3OMt0o2GxLKN6mMMbFRTZOQF8emBYJE2qHRUfds130_assertion description "[RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP936426.RAbZ3G3OMt0o2GxLKN6mMMbFRTZOQF8emBYJE2qHRUfds130_provenance.
- NP936475.RAn3CpMaPPXgVsdDgAZIvWtCCjnPYwpz3Ue92OVwoWjUc130_assertion description "[RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP936475.RAn3CpMaPPXgVsdDgAZIvWtCCjnPYwpz3Ue92OVwoWjUc130_provenance.
- NP650493.RAUIJnW1ideR4epk2FHKY4JI63FfZ1SKD7c7MjJq-r2jU130_assertion description "[RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP650493.RAUIJnW1ideR4epk2FHKY4JI63FfZ1SKD7c7MjJq-r2jU130_provenance.
- NP650505.RAduQEAXkSQJXwmzMbpl6k2FXr9fStqfv7vMKMwpNxbyI130_assertion description "[RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP650505.RAduQEAXkSQJXwmzMbpl6k2FXr9fStqfv7vMKMwpNxbyI130_provenance.
- NP219089.RAv3bKwC52suBh3p-tcqJyurItMNbGcdG3sMJe1TxLp2w130_assertion description "[RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP219089.RAv3bKwC52suBh3p-tcqJyurItMNbGcdG3sMJe1TxLp2w130_provenance.
- NP650508.RAAuOyhLEddS_bj9yKo73iYz3ogk35olpvUPYzP32lYoU130_assertion description "[RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP650508.RAAuOyhLEddS_bj9yKo73iYz3ogk35olpvUPYzP32lYoU130_provenance.
- NP650495.RAjKjL9-pkvWdgBjeQVxvFUbqvDFNXHRcmqDj043AKFsA130_assertion description "[RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP650495.RAjKjL9-pkvWdgBjeQVxvFUbqvDFNXHRcmqDj043AKFsA130_provenance.
- NP284940.RA5-bLRiBwd3XnMiC6jFz9hGrcYvQZLgqnA8iauEbbWAQ130_assertion description "[RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP284940.RA5-bLRiBwd3XnMiC6jFz9hGrcYvQZLgqnA8iauEbbWAQ130_provenance.
- NP219602.RAHLzjtFDdDbU3a3USGiV10JPXfRng5vfR1_ibq8rY6oY130_assertion description "[RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP219602.RAHLzjtFDdDbU3a3USGiV10JPXfRng5vfR1_ibq8rY6oY130_provenance.
- NP650497.RA1eurHDACnxc22D0RifIInBAylZWdy53xJ1omJeksKtE130_assertion description "[RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP650497.RA1eurHDACnxc22D0RifIInBAylZWdy53xJ1omJeksKtE130_provenance.
- NP936434.RA53cjgwvJYczQaB-qO1S4A5TeoK-PiTRs8YNm4ujxbZs130_assertion description "[RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP936434.RA53cjgwvJYczQaB-qO1S4A5TeoK-PiTRs8YNm4ujxbZs130_provenance.